

Charles River Lab (CRL)

\$203.02 (Stock Price as of 12/22/2025)

Price Target (6-12 Months): **\$197.00**

Long Term: 6-12 Months | **Zacks Recommendation:** **Neutral**
(Since: 04/09/25)
Prior Recommendation: Underperform

Short Term: 1-3 Months | **Zacks Rank:** (1-5) **3-Hold**
Zacks Style Scores: VGM: A
Value: B | Growth: B | Momentum: B

Summary

Charles River benefits from consistent demand for its research model services. CRADL's model continues to appeal to clients seeking flexible vivarium space without the burden of building its own internal infrastructure, providing a clear cost-saving value proposition. Strategic acquisitions and collaborations help expand Charles River's capabilities across the drug discovery and early-stage development continuum. Meanwhile, Charles River looks forward to a NAM-enabled future. Our model forecasts a 3% CAGR in its revenues through 2025-2027. However, the company is navigating a challenging biopharmaceutical demand environment where client spending is still constrained. The timing of NHP shipments from both Noveprim and China can lead to quarterly revenue fluctuations. Macroeconomic impacts can also weigh on its results.

Data Overview

52 Week High-Low	\$200.58 - \$91.86
20 Day Average Volume (sh)	762,782
Market Cap	\$9.7 B
YTD Price Change	6.8%
Beta	1.63
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical Services
Zacks Industry Rank	Bottom 35% (156 out of 243)

Last EPS Surprise	4.7%
Last Sales Surprise	2.1%
EPS F1 Est- 4 week change	0.1%
Expected Report Date	02/18/2026
Earnings ESP	0.0%

P/E TTM	18.7
P/E F1	19.9
PEG F1	10.6
P/S TTM	2.4

Price, Consensus & Surprise⁽¹⁾



Sales and EPS Growth Rates (Y/Y %)⁽²⁾



Sales Estimates (millions of \$)⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	992 E	1,033 E	1,022 E	1,017 E	4,064 E
2025	984 A	1,032 A	1,005 A	985 E	4,006 E
2024	1,012 A	1,026 A	1,010 A	1,003 A	4,050 A

EPS Estimates⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	2.38 E	2.74 E	2.62 E	2.94 E	10.68 E
2025	2.34 A	3.12 A	2.43 A	2.31 E	10.20 E
2024	2.27 A	2.80 A	2.59 A	2.66 A	10.32 A

*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, except the estimates, is as of 12/22/2025.

(2) The report's text, the analyst-provided estimates, and the price target are as of 12/09/2025.

Overview

Headquartered in Wilmington, MA, Charles River Laboratories International, Inc. (CRL) is a full service, early-stage contract research organization (CRO). The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts.


The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market.

Charles River currently has three reporting segments: **Discovery and Safety Assessment (DSA)**, **Research Models and Services (RMS)** and **Manufacturing Solutions**.

The DSA segment (60.5% of total revenues in 2024; down 6.3% from 2023) provides services that enable clients to outsource their advanced drug discovery research, related drug development activities and their regulatory-required safety testing of potential new drugs, industrial and agricultural chemicals, consumer products, veterinary medicines and medical devices.

Through the RMS segment (20.5%; up 4.7% from 2023), the company supplies research models to the drug development industry. It also provides a variety of related services that are designed to support clients in the use of research models in drug discovery and development.

Through the Manufacturing segment (19%, up 6.6% from 2023) the company helps ensure the safe production and release of products manufactured by its clients. The Manufacturing segment comprises three businesses: Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.



Reasons To Buy:

▲ **RMS Prospects Bright:** Charles River continues to maintain its position as a global leader in the production and sale of the most widely used research models. Small research models essentially serve as low-cost tools for biomedical research, which supports the company's ability to continue to realize price increases globally. In the third quarter of 2025, revenues increased 6.5% on an organic basis, driven by an increase in large research model product revenues, notably from Noveprim and within China. Revenues from both academic and government client segments also climbed, including a slight rise in North America.

Historically, the CRADL (Charles River Accelerator and Development Lab) service has been one of the largest growth drivers for RMS, but of late, it has been impacted by the overall biopharma demand environment. Despite this, CRADL's business model continues to resonate with clients to access flexible vivarium space without having to invest in internal infrastructure, offering a strong value proposition for those looking to reduce costs and conserve capital. Also, in the quarter, contributions from the GEMS business drove research model services revenues. Clients continue to rely on these services for complex research and genetically modified model colonies. According to our model, RMS revenues are expected to grow 1.8% in 2025.

▲ **DSA, A Potential Growth Driver:** Charles River is the leading global provider of outsourced drug discovery, non-clinical development, and regulated safety testing services, with its extensive expertise in identifying preclinical candidates and safety assessment studies for numerous types of compounds, including cell and gene therapies and small and large molecule pharmaceuticals. The demand for these services is supported by large global pharmaceutical companies' continued shift to outsourced drug development models, alongside mid-size and emerging biotechs, industrial and agrochemical firms, and non-governmental organizations that rely on outsourcing.

Among major acquisitions, Charles River acquired Noveprim, the Mauritius-based provider of non-human primates (NHPs) in 2023, bolstering and diversifying the supply chain for this segment. It also acquired SAMDI Tech, Inc. (SAMDIT), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research.

In the third quarter of 2025, the DSA demand environment remained quite stable, including a net book-to-bill ratio of 0.82, which was identical to the level reported in the second quarter. Cancellation rate also improved and continued to normalize toward historical levels. Charles River is also cautiously optimistic that booking activity for biotech clients will continue to improve. Going by our model, DSA revenues are likely to witness a 2.7% CAGR through 2025-2027.

▲ **Advancing NAM Strategy:** In April 2025, the FDA announced plans to launch a pilot program to reduce animal testing in preclinical safety studies with scientifically validated cell-based and new approach methodologies (NAMs). The vision aligns with Charles River's long-standing mission to enhance efficiency in the drug development process, foster scientific innovation and promote the responsible use of animals in biomedical research. A year earlier, the company had launched an initiative called, Alternative Methods Advancement Project (AMAP), which is dedicated to developing alternatives to the use of animal testing within the drug development process.

For Charles River, broader utilization of NAMs-enabled approaches will be a gradual, long-term transition by its clients, as the scientific capabilities to fully replace animal models do not exist today. The company already has a growing NAMs portfolio that is generating a meaningful amount of revenues, or approximately \$200 million in annual DSA revenues. As client interest in this portfolio continues to build, Charles River is prioritizing to continue expanding this portfolio of premier NAM capabilities through a combination of partnerships, selective M&A and internal development.

▲ **Strategic Deals Drive Growth:** Charles River broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused partnerships and acquisitions. During the third quarter of 2025, the company teamed up with Elly's Team to support fast-track production of therapeutic targeting ultra-rare neurodevelopmental disease. Another two strategic collaborations across its contract development and manufacturing organization (CDMO) — the Parker Institute for Cancer Immunotherapy and with Children's Hospital Los Angeles — are aimed at advancing novel oncology research and development.

This year, Charles River extended its multi-decade collaboration with CHDI Foundation to progress options for the treatment of Huntington's disease and also Deciphex, the AI-powered digital pathology leader. Additionally, Charles River and Akron Bio collaborated to enhance operations with the integration of CGMP materials into the cell therapy platform.

In 2024, the company strengthened its neurological research efforts through multiple collaborations, including with Lundbeck A/S (Lundbeck) and the integration of Insightec's focused ultrasound technology. Additionally, it partnered with the FOXG1 Research Foundation (FRF) to advance its gene therapy through clinical trials. Furthermore, a collaborative relationship with Autobahn Labs established Charles River as the preferred research partner to support their growing pipeline of early-stage, preclinical therapeutics programs.

▲ **Stable Solvency Structure:** Charles River exited the third quarter of 2025 with cash and cash equivalents of \$207 million, while short-term debt payable was nil. This is good news in terms of the company's solvency position, particularly during the time of worldwide macroeconomic complications. Meanwhile, long-term debt dropped 6.3% sequentially, reaching \$2.19 billion. Debt-to-capital ratio was 39.1% compared to 41% in the second quarter. Times interest ratio remained flat at 0.8%.

Both the RMS and DSA segments hold strong potential for Charles River's long-term growth. Strategic acquisitions and collaborations play a central role.

Reasons To Sell:

▼ **NHP Supply Issue Raises Concerns:** Charles River, like the broader biopharmaceutical industry, relies on the access, transport, and safe handling of NHPs in biomedical research facilities to advance new medicines, therapies, and vaccines. China's 2020 export ban on NHPs greatly affected the biomedical research community, particularly in the U.K., Europe, and the United States, limiting access as well as impacting the supply and cost. Before the ban, China was the primary supplier of purpose-bred NHPs, providing nearly 70% for biomedical research

In February 2023, Charles River received a subpoena from the U.S. Department of Justice relating to an investigation into the Cambodian NHP supply chain and voluntarily suspended NHP shipments from Cambodia. In the upcoming quarters as well, the timing of NHP shipments from both Noveprim and China can lead to quarterly revenue fluctuations. Since the sales of these large models are quite profitable, the timing of shipments can have a meaningful impact on the RMS segment's margins every quarter. NHP shipments are expected to create a modest headwind to year-over-year revenue growth in the fourth quarter of 2025, following accelerated shipments in the third quarter.

The global business environment remains challenging. The cambodian NHP supply-related issue continues to dent growth.

▼ **Macroeconomic Condition:** Charles River is experiencing a cautious spending environment, particularly among its global biopharmaceutical and biotechnology clients within the DSA segment, particularly as they reassess their budgets, reprioritize their drug pipelines, and manage their cost structures. In the third quarter of 2025, revenues for small and mid-sized biotech clients declined, reflecting tighter budgets. Moreover, the RMS segment derives certain revenues from academic institutions and research laboratories that depend on funding from agencies like the U.S. National Institutes of Health (NIH). A recent NIH policy, significantly reducing research grants by limiting payments for indirect overhead, has created a risk of delayed client purchasing decisions and adversely affecting Charles River's financial results.

On a broader macroeconomic level, the company is exposed to a difficult operating environment with geopolitical pressure leading to disruptions in economic activity, global supply chains, and labor markets. Charles River is now subject to tariffs on imports from its major supplier countries such as Vietnam, Mauritius, and China. Further, volatile financial market dynamics and significant volatility in the price and availability of goods and services are putting pressure on the company's profitability. Collectively, these factors can drive up its cost and expenses and pressure margins. In the third quarter of 2025, the company's gross margin fell 85 basis points (bps). Our model assumes total operating expenses for Charles River to grow 5.2% in 2025.

▼ **Foreign Exchange Translation Impacts Sales:** Foreign exchange is a major headwind for Charles River as a considerable percentage of its revenues comes from outside the United States. While the company reports in U.S. dollars, its subsidiaries conduct business in various currencies such as the Euro, British Pound, Canadian Dollar, and Mauritian Rupee. The strengthening of the U.S. dollar in recent months has further intensified foreign exchange headwinds.

▼ **Competitive Landscape:** Charles River competes in the marketplace on the basis of its therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation, and global capabilities. The company primarily faces a broad range of competitors of different sizes and capabilities in each of its three business segments. For RMS, it has five main competitors, of which one is a government-funded, not-for-profit entity, one is privately held in Europe, and three are privately held in the United States. For DSA, Discovery Services has three main competitors, two are public companies in China and one is a public company in Europe. Within Safety Assessment, one main competitor is a division of a large public company in the United States. In Manufacturing, each of the company's underlying businesses has several competitors. This fiercely competitive global market impacts the company's market capitalization scenario.

Last Earnings Report

Charles River's Q3 Earnings Top Estimates

Charles River Laboratories International reported third-quarter 2025 adjusted earnings per share of \$2.43, down 6.2% year over year. However, the figure surpassed the Zacks Consensus Estimate by 4.74%.

On a GAAP basis, the company reported earnings of \$1.10 per share compared with the year-ago quarter's level of \$1.33.

FY Quarter Ending **12/31/2024**

Earnings Reporting Date	Nov 05, 2025
Sales Surprise	2.06%
EPS Surprise	4.74%
Quarterly EPS	2.43
Annual EPS (TTM)	10.55

CRL's Q3 Revenues

Revenues totaled \$1.00 billion, which beat the Zacks Consensus Estimate by 2.06%. However, the top line fell 0.5% from the year-ago quarter's level (down 1.6% organically, excluding the impact of foreign currency translation and the divestiture of a small Safety Assessment site in 2024).

CRL's Q3 Segmental Performance in Detail

The company reports under three segments — **Research Models and Services** ("RMS"), **Discovery and Safety Assessment** ("DSA") and **Manufacturing Solutions**.

RMS' revenues totaled \$213.5 million, up 7.9% year over year (up 6.5% organically). The organic growth was primarily due to higher revenues for large research model products. Our model estimated RMS business revenues to be \$210.7 million in the third quarter.

DSA's revenues amounted to \$600.7 million, down 2.3% year over year and 3.1% organically. The organic decline in revenues can be attributed to lower sales volume for both discovery and regulated safety assessment services. Our model projected revenues of \$572.2 million for this segment.

Manufacturing Solutions' revenues totaled \$190.7 million, down 3.1% year over year (down 5.1% organically).

The decrease was mainly due to lower revenues in the CDMO and Biologics Testing businesses, partially offset by higher revenues in the Microbial Solutions business. Our model projected revenues to be \$195.6 million for the third quarter.

CRL's Margin Performance

The gross profit in the reported quarter was \$338.8 million, down 2.9% from the prior-year quarter's level. The gross margin of 33.7% fell 85 basis points (bps) year over year.

Selling, general & administrative expenses dropped 10.8% year over year to \$177.6 million. The adjusted operating profit totaled \$161.2 million, reflecting a 7.6% increase from the prior-year quarter's level. The adjusted operating margin expanded 121 bps to 16%.

CRL's Liquidity Position

Charles River exited the third quarter of 2025 with cash and cash equivalents of \$207.1 million compared with \$182.8 million at the end of the second quarter.

Cumulative net cash provided by operating activities at the end of the third quarter was \$590.1 million compared with \$575.2 million a year ago.

Charles River's 2025 Guidance

For 2025, the company now expects total revenues between (1.5%) and (0.5%), down from the previous estimate of (2.5%)-(0.5%). Organically, revenues are projected between (2.5%) and (1.5%), down from the previous (3%)-(1%) range. The Zacks Consensus Estimate for 2025 revenues is pegged at \$3.98 billion, implying a decline of 1.7%.

Adjusted earnings per share for 2025 is expected in the range of \$10.10-\$10.30 (previously \$9.90-\$10.30). The Zacks Consensus Estimate for the metric is pegged at \$10.17.

Recent News

Charles River Updates on Strategic Review: Nov. 5, 2025

Charles River announced an update on its board of directors' comprehensive strategic review of its business and growth prospects. This includes steps to strengthen and refine the portfolio and maximize financial performance.

Charles River and the Francis Crick Institute Collaborate: July 22, 2025

Charles River and The Francis Crick Institute (Crick) announced a new collaboration on Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.

Charles River and X-Chem Team Up: Oct. 20, 2025

Charles River announced a strategic collaboration with X-Chem, Inc. to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics.

Valuation

Charles River's shares are up 1.4% and down 5.0% in the year-to-date period and the trailing 12-month period, respectively. Stocks in the Zacks sub-industry are up 6.2% while the Zacks Medical sector is up 6% in the year-to-date period. Over the past year, the Zacks sub-industry is up 0.4% and sector is down 1.1%.

The S&P 500 index is up 19.2% in the year-to-date period and up 16.3% in the past year.

The stock is currently trading at 17.5X Forward 12-months earnings, which compares to 16.4X for the Zacks sub-industry, 20.8X for the Zacks sector and 23.6X for the S&P 500 index.

Over the past five years, the stock has traded as high as 40.5X and as low as 10.4X, with a 5-year median of 18.9X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$197 price target reflects 18.4X forward 12-months earnings.

The table below shows summary valuation data for CRL.

Valuation Multiples - CRL					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	17.52	16.35	20.84	23.59
	5-Year High	40.48	18.78	23.62	23.78
	5-Year Low	10.39	13.21	17.88	15.73
	5-Year Median	18.88	15.44	20.69	21.21
P/S F12M	Current	2.27	0.47	2.15	5.33
	5-Year High	6.03	0.92	2.41	5.50
	5-Year Low	1.26	0.43	2.01	3.83
	5-Year Median	2.60	0.62	2.64	5.05
P/B TTM	Current	2.70	2.02	3.95	8.56
	5-Year High	9.94	3.09	6.08	9.16
	5-Year Low	1.53	1.65	3.57	6.60
	5-Year Median	3.42	2.25	4.53	8.05

As of 12/08/2025

Source: Zacks Investment Research

Industry Analysis⁽¹⁾ Zacks Industry Rank: Bottom 35% (156 out of 243)



Top Peers⁽¹⁾

Company (Ticker)	Rec	Rank
Medpace Holdings, In...(MEDP)	Outperform	2
AMN Healthcare Servi...(AMN)	Neutral	3
Bausch + Lomb Corpor...(BLCO)	Neutral	3
ICON PLC (ICLR)	Neutral	3
IQVIA Holdings Inc. (IQV)	Neutral	3
Surgery Partners, In...(SGRY)	Neutral	4
PACS Group, Inc. (PACS)	Underperform	5
Bio-Techne Corp (TECH)	Underperform	4

Industry Comparison⁽¹⁾ Industry: Medical Services

	CRL	X Industry	S&P 500	BLCO
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral
Zacks Rank (Short Term)	3	-	-	3
VGM Score	A	-	-	B
Market Cap	9.70 B	342.77 M	38.78 B	6.01 B
# of Analysts	7	3	22	5
Dividend Yield	0.00%	0.00%	1.39%	0.00%
Value Score	B	-	-	B
Cash/Price	0.02	0.14	0.04	0.06
EV/EBITDA	14.67	4.59	14.61	17.08
PEG Ratio	10.33	1.67	2.19	1.46
Price/Book (P/B)	2.84	1.83	3.32	0.92
Price/Cash Flow (P/CF)	9.08	10.88	15.20	9.07
P/E (F1)	19.32	15.44	19.70	31.45
Price/Sales (P/S)	2.41	1.12	3.10	1.21
Earnings Yield	5.19%	3.43%	5.07%	3.18%
Debt/Equity	0.64	0.17	0.56	0.76
Cash Flow (\$/share)	21.70	0.04	8.99	1.87
Growth Score	B	-	-	A
Hist. EPS Growth (3-5 yrs)	2.51%	-4.19%	8.16%	-26.90%
Proj. EPS Growth (F1/F0)	-1.16%	23.43%	8.50%	-6.90%
Curr. Cash Flow Growth	28.58%	-1.23%	6.86%	-1.49%
Hist. Cash Flow Growth (3-5 yrs)	15.82%	7.19%	7.43%	NA
Current Ratio	1.37	1.60	1.19	1.51
Debt/Capital	39.49%	26.70%	38.01%	43.09%
Net Margin	-2.07%	-1.25%	12.78%	-6.13%
Return on Equity	15.78%	-6.66%	17.00%	2.42%
Sales/Assets	0.53	0.76	0.53	0.36
Proj. Sales Growth (F1/F0)	-1.10%	0.00%	5.81%	6.00%
Momentum Score	B	-	-	F
Daily Price Chg	1.66%	0.00%	0.88%	0.47%
1 Week Price Chg	2.09%	0.00%	0.10%	-0.06%
4 Week Price Chg	17.55%	0.00%	3.51%	12.67%
12 Week Price Chg	32.65%	-1.10%	2.87%	17.10%
52 Week Price Chg	6.08%	-5.75%	15.24%	-5.67%
20 Day Average Volume	762,782	337,241	3,013,825	337,241
(F1) EPS Est 1 week change	0.01%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	0.13%	0.00%	0.00%	0.00%
(F1) EPS Est 12 week change	0.27%	0.00%	0.69%	-1.57%
(Q1) EPS Est Mthly Chg	-0.12%	0.00%	0.00%	-2.19%

Analyst Earnings Model⁽²⁾

Charles River Laboratories International, Inc. (CRL)

In \$MM, except per share data

	2022A	2023A	2024A	2025E				2026E				2027E		
	FY	FY	FY	1QA	2QA	3QA	4QE	FY	1QE	2QE	3QE	4QE	FY	FY
FY Ends December 31st	Dec-22	Dec-23	Dec-24	31-Mar-25	30-Jun-25	30-Sep-25	31-Dec-25	Dec-25	31-Mar-26	30-Jun-26	30-Sep-26	31-Dec-26	Dec-26	Dec-27
Income Statement														
Service	\$3,216.9	\$3,440.0	\$3,304.1	\$797.9	\$840.8	\$808.0	\$805.9	\$3,252.7	\$810.7	\$847.4	\$843.0	\$832.4	\$3,333.5	\$3,470.2
Product	\$759.2	\$689.4	\$745.9	\$186.2	\$191.3	\$196.8	\$178.6	\$753.0	\$181.5	\$185.4	\$178.5	\$184.7	\$730.1	\$782.0
Total Revenue	\$3,976.1	\$4,129.4	\$4,050.0	\$984.2	\$1,032.1	\$1,004.9	\$984.5	\$4,005.7	\$992.2	\$1,032.8	\$1,021.5	\$1,017.1	\$4,063.6	\$4,252.3
Organic Growth	13.4%	6.5%	(2.8%)	(1.8%)	(0.5%)	(1.6%)	(4.0%)	(2.0%)	(1.4%)	(2.2%)	(0.6%)	3.3%	(0.2%)	4.6%
Currency	(3.5%)	0.2%	0.1%	(0.9%)	1.2%	1.3%	2.2%	1.0%	2.2%	2.2%	2.2%	0.0%	1.7%	0.0%
Acquisitions/Divestitures	2.4%	(1.4%)	0.8%	0.0%	0.0%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cost of Services	\$2,143.3	\$2,296.0	\$2,345.8	\$577.4	\$584.9	\$572.6	\$547.7	\$2,282.6	\$553.9	\$558.0	\$565.4	\$562.3	\$2,239.5	\$2,350.2
Cost of Products	\$370.1	\$330.9	\$372.4	\$89.0	\$90.2	\$93.4	\$85.3	\$357.9	\$97.5	\$99.2	\$96.5	\$79.2	\$372.4	\$379.2
Cost of Goods Sold	\$2,513.4	\$2,626.9	\$2,718.2	\$666.4	\$675.1	\$666.1	\$633.0	\$2,640.6	\$651.3	\$657.2	\$661.8	\$641.5	\$2,611.9	\$2,729.3
Gross Profit	\$1,462.7	\$1,502.6	\$1,331.8	\$317.7	\$357.1	\$338.8	\$351.5	\$1,365.1	\$340.9	\$375.6	\$359.7	\$375.6	\$1,451.7	\$1,522.9
Selling, General & Administrative	\$665.1	\$747.9	\$751.0	\$177.8	\$191.5	\$177.6	\$182.5	\$729.5	\$162.0	\$170.2	\$165.3	\$165.5	\$663.0	\$710.0
Amortization of Intangible Assets	\$146.6	\$137.4	\$138.5	\$65.3	\$65.4	\$27.4	\$48.7	\$206.8	\$51.2	\$49.5	\$45.0	\$49.1	\$194.9	\$201.4
Total Operating Expenses	\$811.7	\$885.3	\$889.5	\$243.1	\$256.9	\$205.0	\$231.3	\$936.3	\$213.2	\$219.7	\$210.4	\$214.6	\$857.9	\$911.3
Adjusted EBITDA	\$1,137.8	\$1,152.9	\$1,167.7	\$308.6	\$347.7	\$282.9	\$273.5	\$1,212.7	\$285.3	\$312.2	\$296.9	\$316.2	\$1,210.7	\$1,252.4
EBITDA, GAAP	\$954.8	\$931.4	\$589.1	\$195.0	\$219.6	\$219.0	\$224.8	\$858.4	\$234.1	\$262.7	\$251.9	\$267.1	\$1,015.8	\$1,051.0
Depreciation & Amortization	\$303.9	\$314.1	\$361.7	\$120.4	\$119.5	\$85.2	\$104.5	\$429.6	\$106.4	\$106.9	\$102.6	\$106.1	\$422.0	\$439.4
Operating Income, Non-GAAP	\$834.0	\$838.8	\$805.9	\$188.2	\$228.2	\$197.7	\$169.0	\$783.1	\$178.9	\$205.4	\$194.3	\$210.1	\$788.7	\$813.0
Operating Income, GAAP	\$651.0	\$617.3	\$227.3	\$74.7	\$100.1	\$133.8	\$120.2	\$428.8	\$127.7	\$155.9	\$149.3	\$161.0	\$593.8	\$611.6
Interest Income	\$0.8	\$5.2	\$8.6	\$1.4	\$1.1	\$1.4	\$1.4	\$5.3	\$1.3	\$1.4	\$1.4	\$1.4	\$5.5	\$5.7
Interest Expense	\$59.3	\$136.7	\$126.3	\$27.9	\$30.0	\$25.4	\$26.3	\$109.5	\$27.1	\$28.0	\$27.2	\$27.4	\$109.7	\$114.5
Interest Expense/(Income), Net	\$58.5	\$131.5	\$117.7	\$26.5	\$28.9	\$24.0	\$24.9	\$104.2	\$25.8	\$26.6	\$25.8	\$26.0	\$104.2	\$108.7
Other Expense/(Income), Net	(\$30.5)	(\$95.5)	\$16.5	\$12.2	(\$0.2)	\$22.6	\$4.5	\$39.2	\$9.8	\$9.5	\$11.8	\$8.9	\$39.9	\$41.7
Total Interest & Other Expense/(Income), Net, Non-GAAP	\$119.5	\$127.2	\$121.1	\$32.1	\$27.3	\$26.4	\$27.7	\$113.5	\$28.2	\$28.2	\$28.1	\$28.3	\$112.8	\$117.8
Total Interest & Other Expense/(Income), Net, GAAP	\$28.0	\$36.0	\$134.2	\$38.7	\$28.7	\$46.6	\$29.4	\$143.4	\$35.6	\$36.1	\$37.5	\$34.9	\$144.1	\$150.4
Pre-Tax Income, Non-GAAP	\$714.5	\$711.7	\$684.9	\$156.1	\$200.9	\$171.3	\$141.2	\$669.6	\$150.8	\$177.2	\$166.2	\$181.8	\$675.9	\$695.2
Pre-Tax Income, GAAP	\$623.0	\$581.3	\$93.1	\$36.0	\$71.4	\$87.2	\$90.9	\$285.5	\$92.1	\$119.8	\$111.8	\$126.0	\$449.7	\$461.2
Income Tax, Non-GAAP	\$137.5	\$157.0	\$145.6	\$35.4	\$45.6	\$48.6	\$28.0	\$157.5	\$29.8	\$35.1	\$32.9	\$36.0	\$133.8	\$137.6
Income Tax, GAAP	\$130.4	\$100.9	\$67.8	\$10.1	\$18.7	\$31.6	\$16.1	\$76.6	\$16.3	\$21.2	\$19.8	\$22.3	\$79.6	\$81.6
Tax Rate, Non-GAAP	19.2%	22.1%	21.3%	22.7%	22.7%	28.3%	19.8%	23.5%	19.8%	19.8%	19.8%	19.8%	19.8%	19.8%
Tax Rate, GAAP	20.9%	17.4%	72.8%	28.1%	26.2%	36.3%	17.7%	26.8%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%
Net Income Before Non-Controlling Interests	\$492.6	\$480.4	\$25.3	\$25.9	\$52.7	\$55.6	\$74.8	\$208.9	\$75.8	\$98.6	\$92.0	\$103.7	\$370.1	\$379.5
Non-Controlling Interests	\$6.4	\$5.7	\$3.1	\$0.4	\$0.4	\$1.1	\$1.1	\$3.0	\$1.1	\$1.1	\$1.1	\$1.1	\$4.5	\$4.5
Net Income, Non-GAAP	\$570.6	\$548.9	\$532.9	\$119.1	\$154.0	\$120.3	\$114.4	\$507.8	\$117.5	\$135.7	\$129.5	\$145.2	\$527.9	\$558.4
Net Income, GAAP	\$486.2	\$474.6	\$22.2	\$25.5	\$52.3	\$54.4	\$73.6	\$205.9	\$74.7	\$97.4	\$90.8	\$102.6	\$365.6	\$375.0
Net Income Available to Charles River Laboratories International, Inc.			\$10.3	\$25.5	\$52.3	\$54.4	\$73.6	\$205.9	\$74.7	\$97.4	\$90.8	\$102.6	\$365.6	\$375.0
Diluted Shares Outstanding	51.3	51.5	51.6	50.9	49.3	49.4	49.4	49.8	49.4	49.4	49.4	49.4	49.4	49.4
Diluted EPS, Non-GAAP	\$11.12	\$10.67	\$10.32	\$2.34	\$3.12	\$2.43	\$2.31	\$10.20	\$2.38	\$2.74	\$2.62	\$2.94	\$10.68	\$11.30
Diluted EPS, GAAP	\$9.48	\$9.22	\$0.20	\$0.50	\$1.06	\$1.10	\$1.49	\$4.15	\$1.51	\$1.97	\$1.84	\$2.08	\$7.40	\$7.59

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	B
Growth Score	B
Momentum Score	B
VGM Score	A

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.